Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up more than 25%. The gain has similarly shown strong outperformance relative to the S&P 500, with recent results driving positive momentum post-earnings.
Johnson & Johnson has delivered a 68.9% total return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples lean the other way. Over 5 years, Johnson & Johnson has returned 68.9%, which puts the recent share price near the upper end of its longer term journey. Pipeline progress in areas such as major depressive disorder therapies and new medical technologies like surgical robotics can...
AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
Medicare's IRMAA surcharge punishes a single dollar of overage with a full bracket jump and no phase-in, yet some retirees collect six figures annually and never trigger it. The strategy depends on how income is classified, not how much arrives.
The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]
Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.
The pharmaceutical giant just increased its dividend by 3.1%, now paying $5.36 a share annually.
Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.
Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.
Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.
Four dividend giants from energy and pharma quietly generate the bulk of HDV's income, but their balance sheets and payout coverage look nothing alike. Before trusting that 3% yield, it pays to know which checks are ironclad and which carry a hidden catch.
Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson’s focus on higher growth therapeutic and medtech areas that are important for its long term...
Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of "Crowding Out Competitors" is strategically smart.
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.
Oppenheimer argues Ottava and Hugo pose no near-term threat to da Vinci
These stocks can help you withstand (almost) any storm.
Johnson & Johnson has surged more than 50% in a year and now sits within striking distance of its 52-week high, but a closer look at the valuation, insider activity, and pipeline pressures raises a pointed question about who actually wins from here.
Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.
J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.
For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.
In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
